Niaspan: profile and news

Kos Reports Summary Results of Key Phase IV Research and ... Feb 23, 2006
...-- Kos' optimized Niaspan(R) modified formulation ("MF") shows an improved overall flushing profile vs. commercialized Niaspan, with ... - Genetic Engineering News,

Kos Reports Summary Results of Key Phase IV Research and ... Feb 23, 2006
...data from a study with an optimizedNiaspan(R) MF dosage strength and data from the COMPELL (COMParativeEffects on Lipid Levels of Niaspan and Statins Versus ... - Finanzen.net,

Kos Reports Summary Results of Key Phase IV Research and ... Feb 23, 2006
...results from two studies that represent significant milestones in its research and development activities: data from a study with an optimized Niaspan(R) MF ... - PharmaLive.com (press release),

Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ... Feb 23, 2006
...of the American Heart Association Meeting, Kos also announced the results of the ARBITER 3 clinical study, which demonstrated that adding Niaspan(R) to a ... - Genetic Engineering News,

Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ... Feb 23, 2006
...of the American Heart Association Meeting, Kos also announcedthe results of the ARBITER 3 clinical study, which demonstrated thatadding Niaspan(R) to a statin ... - Finanzen.net,

Kos improves existing cholesterol drug Feb 24, 2006
Miami-based drugmaker Kos Pharmaceuticals has received positive results from a study of its already-approved cholesterol drug Niaspan confirming the drug's ... - Pharmaceutical Business Review

Kos cholesterol drug meets main goals in study Feb 23, 2006
CHICAGO, Feb 23 (Reuters) - Kos Pharmaceuticals Inc. (KOSP.O: Quote, Profile, Research) on Thursday said its Niaspan drug reached its main goal of reducing so ... - Reuters

The Fat Hits the Fire at Kos Feb 6, 2006
Kos Pharmaceuticals had been enjoying a comfortable ride on sales of Niaspan, the only drug approved by the Food and Drug Administration to raise blood levels ... - Business New Jersey (subscription),

Medicare Q&A: 'Plan D' questions and answers Feb 19, 2006
Q: I tried to fill a prescription for Niaspan under Part D and found that although the drug was listed in my insurance company's formulary, Medicare had ... - Austin American-Statesman (subscription),

Choosing the right medications Feb 3, 2006
Q: I have heart disease and my doctor has put me on Niaspan. ... How do you feel about taking Niaspan, and could a strict diet work without this medication? ... - Fort Wayne News Sentinel,

Part D still a mystery despite research Feb 17, 2006
...effect Jan. 1. Of the six medications Grunberg takes, the only one she has not been able to receive is the drug Niaspan. One of ... - Ithaca Journal,

Kos Announces Presentation at the Lehman Brothers Ninth Annual ... Mar 1, 2006
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Genetic Engineering News,

GPs open up patient files to drug firms Feb 4, 2006
The representative’s search of files identified 40 patients who might benefit from a new Merck drug, Niaspan. Niaspan is designed ... - Times Online,

Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006
...resulting from the Company's agreement with Teva, as well as royalties and fees earned under its April 2005 agreements with Kos relating to the Niaspan(R) and ... - MSN Money

Medicare slows cash flow Feb 13, 2006
Given that, she didn’t make an issue about having to pay $58.16 out-of-pocket for her month supply of cholesterol medication Niaspan. ... - Fort Wayne Journal Gazette,

@Byline writer:Officials worry Medicare plans will be changed ... Feb 17, 2006
Fierberg said CMS did exclude Niaspan and Niacor from drug plans because they are prescription vitamins, which are excluded from Part D. However, that was a ... - Bismarck Tribune,

Rob Gordon, Charlotte Roy Join Harrington Group Feb 16, 2006
Gordon has developed new promotional positioning, messaging and communications materials for pharmaceutical products such as Toprol-XL, Niaspan and Altoprev ... - PharmaLive.com (press release),

Kos Announces Presentation at the Deutsche Bank Small Cap Growth ... Feb 6, 2006
The Company currently markets Niaspan(R) andAdvicor(R) for the treatment of cholesterol disorders, Azmacort(R) forthe treatment of asthma, Cardizem(R)LA for ... - Finanzen.net,

First Horizon Evaluates Triglide Drug Combo Jan 26, 2006
...the effects of a single dose of Merck & Co's Zocor (simvastatin), Pfizer's Lipitor (atorvastatin calcium), and Kos Pharmaceuticals' Niaspan (niacin) on the ... - International News Service,

Harry Rush Jan 22, 2006
...to $329.79. Lipitor for cholesterol, $45; Niaspan for cholesterol, $161.20; Aggrenox to prevent another stroke, $123.59. Atenolol ... - Richmond Times Dispatch,

EDITORIAL >> Huckabee's plea for help Jan 18, 2006
For example, heart patients whose only help was a drug called Niaspan, which raised levels of good cholesterol, learned from their druggist that the government ... - Arkansas Leader,

Open-Label Study Shows No Significant Effects on the ... Jan 19, 2006
The open-label study to evaluate the effect of administering a single dose of Niaspan* (niacin extended-release tablets), Zocor** (simvastatin) and Lipitor ... - PR Newswire (press release),

'Next frontier' in medicine: artery-clearing drugs Jan 9, 2006
...levels. A prescription form of niacin, Niaspan, by Kos Pharmaceuticals, raises HDL by 15 percent to 30 percent, depending on the dose. - News-Leader.com,

No Significant Effects on the Pharmacokinetics of a Single Dose of ... Jan 19, 2006
The study evaluated the effect of administering a single dose of Niaspan* (niacin extended-release tablets), Zocor** (simvastatin) and Lipitor*** (atorvastatin ... - DG News

`Good' Cholesterol Pills May Help Drugmakers' Financial Health 12 Dec 2005
Dec. 12 (Bloomberg) -- Kos Pharmaceuticals Inc.'s Niaspan is the only US-marketed drug to prevent heart disease by boosting ``good'' cholesterol. ... - Bloomberg

Kos Reports on New Research Presented at AHA: Raising HDL-C or '' ... Nov 15, 2005
...presented today at the 2005 Scientific Sessions of the American Heart Association (AHA) demonstrating that adding the HDL-raising therapy Niaspan(R) (niacin ... - Business Wire (press release),

Koenig likes Kos, Hyperion, Affiliated Managers Group Dec 8, 2005
...(SYMB:KOSP), based in Cranberry, NJ. The company's flagship product is the combination cholesterol drug Niaspan, which accounts for 80% of revenue, he said. ... - New York Daily News,

Combination Treatment Shown for First Time to Cause Regression of ... Nov 15, 2005
DALLAS, Texas, November 15 /PRNewswire-FirstCall/ -- - New Study of NIASPAN(R) (Prolonged-Release Nicotinic Acid) Plus Statin A new study has shown for the ... - PR Newswire (press release),

Combination Treatment Shown for First Time to Cause Regression of ... Nov 16, 2005
...first time that reversal of atherosclerosis - a primary cause of stroke and heart attacks - can be achieved with a combination of NIASPAN (prolonged-release ... - PharmaLive.com (press release),

Upgrade boosts Kos Pharmaceuticals stock Nov 22, 2005
The drug would be a direct competitor to Kos' best selling drug Niaspan, which also raises good cholesterol. Niaspan accounted for ... - BusinessWeek

UPDATE 1-Kos HDL-cholesterol drug cuts neck-artery plaque Nov 15, 2005
Reuters) - Plaque shrank in the neck arteries of heart patients taking Kos Pharmaceuticals Inc.'s (KOSP.O: Quote, Profile, Research) drug Niaspan along with a ... - Reuters

Kos HDL-cholesterol drug cuts neck-artery plaque Nov 15, 2005
DALLAS (Reuters) - Plaque shrank in the neck arteries of heart patients taking Kos Pharmaceuticals Inc.'s drug Niaspan along with a statin cholesterol drug ... - ABC News

High Doses of Lipitor Questioned in Heart Study Nov 15, 2005
15 (Reuters) - Plaque shrank by about 5 percent in the neck arteries of heart patients taking the drug Niaspan, made by Kos Pharmaceuticals, along with a ... - New York Times,

Can Good Cholesterol Cure Big Pharma? Nov 29, 2005
Instead, Taylor argues that adding Niaspan, a delayed release niacin made by Kos, cut heart attacks further. A study he presented ... - Forbes

Kos Reports on Promising Data Presented at AHA: New Compound ... Nov 14, 2005
..."We are proud of our pioneering developments in the cholesterol market, specifically with Niaspan(R) and Advicor(R), highly differentiated products aimed at ... - Genetic Engineering News,

Kos Reports on Promising Data Presented at AHA: New Compound ... Nov 14, 2005
..."We are proud of our pioneering developments in the cholesterolmarket, specifically with Niaspan(R) and Advicor(R), highlydifferentiated products aimed at ... - Finanzen.net,

StreetNotes: A Daily Roundup of Street Research Nov 30, 2005
Hold rating. The company is well positioned, offering a portfolio of therapies targeting HDL, namely Niaspan and Advicor. INCO downgraded ... - TheStreet.com

A New Focus: "Good Cholesterol" Nov 15, 2005
Another study presented at the meeting demonstrated the advantages of raising HDL. Niaspan, made by Kos Pharmaceuticals (KOSP), targets HDL. ... - BusinessWeek

Duramed Completes Acquisition of FEI Women's Health and ParaGard(R ... Nov 10, 2005
In addition to ParaGard(R), the Specialty Sales Force will detail Niaspan(R) and Advicor(R) under the Company's agreements with Kos Pharmaceuticals, Inc., as ... - PR Newswire (press release),

Duramed Completes Acquisition of FEI Women's Health and ParaGard(R ... Nov 10, 2005
In addition to ParaGard®, the Specialty Sales Force will detail Niaspan® and Advicor® under the Company's agreements with Kos Pharmaceuticals, Inc., as well ... - Yahoo! News (press release)

Kos Paying Jerini $27M For US Icatibant Rights Nov 7, 2005
56 percent to a record $205.1 million, up from $131.9 million for the third quarter of 2004, thanks to growth of the cholesterol products Niaspan and Advicor ... - BioWorld Online (subscription),

Kos Pharmaceuticals To Report Third Quarter Results On November 3 ... Oct 6, 2005
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Genetic Engineering News,

FIVE GREEK AMERICANS ON THE LIST WITH THE 400 RICHEST PEOPLE IN ... Sep 29, 2005
...a drug for asthma. In 1988, he founded the firm Kos and in 1997 discovered a drug for cholesterol known as "Niaspan". He is the ... - Macedonian Press Agency,

Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
CEO. "Among other milestones during the year was the settlement of our Niaspan(R) patent challenge with Kos Pharmaceuticals, Inc. ... - PR Newswire (press release),

Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
CEO. "Among other milestones during the year was the settlement of our Niaspan® patent challenge with Kos Pharmaceuticals, Inc. ... - Yahoo! News (press release)

Low-Carb Can Raise HDL Levels Without Cholesterol Medication Sep 4, 2005
Singapore is the first Asian country to approve the use of Niaspan, an extended-release form of the prescription drug Niacin. According ... - The Common Voice,

Doubling up in battle to beat cholesterol Aug 26, 2005
It also appears to be more potent than currently available combinations such as Advicor and the pipeline drug KS-01-019 (simvastatin + Niaspan) which are ... - Pharmaceutical Business Review

Research and Markets: Ophthalmology - Allergan / Pharmacopeia Tie ... Aug 24, 2005
...market shift... -- Opinion: Kos Pharmaceuticals: Niaspan combination could offer another string to its cardio bow... -- Opinion: Ophthalmology ... - PharmaLive.com (press release),

Did drug fuel memory loss? Aug 16, 2005
Three different ones have given me peripheral neuropathy (pins and needles). On Niaspan and Zetia my total cholesterol is 160, with bad LDL at 97. ... - Jackson Clarion Ledger,

Kos posts better-than-expected 2Q profit Aug 4, 2005
Revenue increased 49 percent to $179.4 million from $120.3 million, driven by $136.2 million in sales of the company's cholesterol products, Niaspan and Advicor ... - BusinessWeek

Kos Pharmaceuticals: Niaspan combination could offer another ... Jul 7, 2005
Kos Pharmaceuticals [KOSP] has announced the start of a landmark study to evaluate whether combination therapy with Kos' Niaspan (niacin extended-release ... - Pharmaceutical Business Review

Kos Posts Better-Than-Expected 2Q Profit Aug 4, 2005
...increased 49 percent to $179.4 million from $120.3 million, boosted by strong sales and prescription growth of Kos' cholesterol products, Niaspan and Advicor. ... - Forbes

Kos Pharmaceuticals Announces Commencement of Landmark Long-Term ... Jul 6, 2005
...(Nasdaq:KOSP) announced today the commencement of a landmark study to evaluate whether combination therapy with Kos' Niaspan(R) (niacin extended-release tablets ... - PharmaLive.com (press release)

Combating heart disease by increasing good cholesterol levels Jul 28, 2005
...available. Niaspan, a drug recently approved by the Health Sciences Authority was shown to raise good cholesterol level by 20%. ... - Radio Singapore International

Some have memory problems on drug Aug 4, 2005
Three different ones have given me peripheral neuropathy (pins and needles). On Niaspan and Zetia my total cholesterol is 160, with bad LDL at 97. ... - Daily Press

Priced Out Of Heart Disease Jul 6, 2005
...agency, and Kos Pharmaceuticals (nasdaq: KOSP - news - people ), a small drug company, are announcing a 3,300-patient trial testing Kos' Niaspan, a specialized ... - Forbes

Nisapan To Increase Revenues for Kos Pharmaceuticals Jul 13, 2005
The landmark study will evaluate whether combination therapy with Kos' Niaspan (niacin extended-release tablets) and simvastatin (marketed as Zocor by Merck & ... - PharmaLive.com (press release)

NHLBI Study Will Examine Benefits of Raising HDL-C and Lowering ... Jul 6, 2005
...large study to measure the independent effect of treating HDL-C and triglycerides with a combination of extended-release niacin (prescription Niaspan(R)) and ... - PharmaLive.com (press release)

Study Focuses on Increasing Low Levels of Good Cholesterol to ... Jul 7, 2005
...study to measure the independent effect of treating HDL-C and triglycerides with a combination of extended-release niacin (with the trade name Niaspan(R)) and ... - Canada NewsWire (press release)

NHLBI Study Will Examine Benefits of Raising HDL-C and Lowering ... Jul 5, 2005
...to measure the independent effect of treating HDL-C and triglycerides with a combination of extended-release niacin (prescription Niaspan®) and simvastatin ... - Yahoo News (press release)

Niacin may be weapon in cholesterol fight Jul 6, 2005
...will receive either simvastatin, the generic name of Merck & Co.'s Zocor cholesterol reducer or Kos Pharmaceuticals' simvastatin plus Niaspan, an extended ... - Science Daily (press release)

Kos Pharmaceuticals to Report Second Quarter Results on August 4 ... Jul 6, 2005
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - PharmaLive.com (press release)